In the global pharmaceutical industry, there were 401 M&A deals announced in Q2 2024, worth a total value of $34.5bn, according to GlobalData’s Deals Database. The $4.9bn acquisition of Alpine Immune Sciences by Vertex Pharmaceuticals was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
Smarter leaders trust GlobalData
In value terms, M&A activity decreased by 49% in Q2 2024 compared with the previous quarter’s total of $68.1bn and fell by 38% as compared to Q2 2023. Related deal volume decreased by 9% in Q2 2024 versus the previous quarter and was 21% lower than in Q2 2023.
Notably, healthcare-related deals accounted for a 34% share of the global pharmaceutical industry’s M&A activity in Q2 2024, up 2% over the previous quarter.
The top-ranked financial advisors supporting these M&A deals in H1 2024 were Centerview Partners; Lazard; Goldman Sachs Group with 11, 11, 9 deals respectively.
The top-ranked legal advisors supporting these M&A deals in H1 2024 were Goodwin Procter; Kirkland & Ellis; Cooley with 18, 13, 10 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2024 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.
